Hi Kjt
Two problems with the above. Firstly, the RBSQ was already agreed by FDA, and met. The idea the FDA is going to change the goalposts after the fact doesn't make any sense.
Changing the goalposts is what Acadia would argue the FDA did in relation to their Nuplazi dementia-related psychosis filing rejection. In its decision, the agency acknowledged that Nuplazid met the primary endpoint of the Harmony study in a broader psychosis population, but it flagged “limitations in the interpretability” of the results, the company said. In that trial, Nuplazid met its primary endpoint of extending time to relapse in patients with dementia-related psychosis. The FDA last year rejected the drug in that use, with reviewers citing concerns over a lack of statistical significance in some patient subgroups of which Acadia were not aware was required.
https://www.fiercepharma.com/pharma/acadias-nuplazid-gets-second-fda-rejection-alzheimers-disease-psychosis-treatment
- Forums
- ASX - By Stock
- NEU
- Media News
Media News, page-44
-
- There are more pages in this discussion • 178 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
(20min delay)
|
|||||
Last
$15.11 |
Change
0.755(5.26%) |
Mkt cap ! $1.927B |
Open | High | Low | Value | Volume |
$14.35 | $15.18 | $14.35 | $4.504M | 302.3K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 528 | $15.10 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$15.11 | 563 | 11 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 376 | 15.080 |
7 | 652 | 15.070 |
3 | 408 | 15.060 |
4 | 393 | 15.050 |
3 | 394 | 15.040 |
Price($) | Vol. | No. |
---|---|---|
15.100 | 709 | 11 |
15.110 | 966 | 6 |
15.120 | 453 | 3 |
15.130 | 1298 | 6 |
15.140 | 735 | 4 |
Last trade - 14.35pm 27/09/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |